logo
logo
NVST stock ticker logo

Envista Holdings Corporation

NYSE•NVST
CEO: Mr. Stephen Keller
板块: Healthcare
行业: Medical - Equipment & Services
上市日期: 2019-09-18
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
联系方式
Building E, 200 South Kraemer Boulevard, Brea, CA, 92821-6208, United States
714-817-7000
envistaco.com
市值
$4.59B
市盈率 (TTM)
97.7
36.9
股息率
--
52周最高
$30.42
52周最低
$14.22
52周范围
85%
排名40Top 42.0%
4.1
F-Score
改良版 Piotroski 分析
基于 9 年期基本面
一般 • 4.1 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2017-2025

财务仪表盘

Q4 2025 数据

营业收入

$750.60M+0.00%
近4季度走势

每股收益

$0.20+0.00%
近4季度走势

自由现金流

$91.70M+0.00%
近4季度走势

2025 Annual 财报亮点

核心亮点

Revenue Growth Total sales reached $2.72B USD in 2025, reflecting a strong 8.3% GAAP growth compared to the prior year.
Profitability Rebound Net income was $47.0M USD, successfully reversing the substantial $1.12B net loss recorded in 2024 operations.
Impairment Absence Zero goodwill impairment recorded in 2025 versus $1.15B goodwill and intangible asset charge recognized in 2024.
Core Sales Strength Core sales grew 6.5% USD, driven by Specialty Products segment achieving 6.3% growth for the fiscal year.

关注风险

Global Economic Volatility Global economy, inflation, and interest rates may adversely affect customer demand and utilization rates across served markets.
Trade Policy Uncertainty Trade disputes, tariffs, and protectionism increase sourcing costs and restrict market access across international operations.
Cybersecurity Incident Risk IT system breaches or ransomware attacks could seriously harm operations, cause data loss, and result in reputational damage.
Distributor Concentration Loss of key distributor Henry Schein, accounting for 12% of 2025 sales, poses a material concentration risk to revenue streams.

前瞻展望

Strategic Growth Investment Investing in innovation, commercialization, and clinical education remains a key priority to accelerate overall business growth trajectory.
Emerging Market Focus Continue investing in emerging markets, which represented 22% of 2025 total sales volume, expecting strong future growth driver.
Operational Efficiency Focus Utilizing Envista Business System (EBS) to improve manufacturing performance and streamline overall operational cost structure.
Recent Acquisition Integration Completed Versah acquisition for approximately $55.0M cash in February 2026 to expand portfolio with innovative dental technology.

同行对比

营业收入 (TTM)

ALHC stock ticker logoALHC
$3.95B
+46.1%
XRAY stock ticker logoXRAY
$3.68B
-3.0%
NVST stock ticker logoNVST
$2.72B
+8.3%

毛利率 (最新季度)

QURE stock ticker logoQURE
92.2%
+33.9pp
SUPN stock ticker logoSUPN
89.1%
-15.2pp
RARE stock ticker logoRARE
86.0%
-2.4pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
CGON$4.99B-29.0-22.9%0.9%
TMDX$4.80B25.253.9%44.0%
NVST$4.59B97.71.5%30.1%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
6.8%
稳定增长
4季度净利润复合增长率
22.3%
盈利能力强劲提升
现金流稳定性
100%
现金流表现优异

深度研究

下次财报:2026年4月29日
|
每股收益:-
|
营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据